Abstract: |
We have used 31P NMR spectroscopy to study 22 patients with suspected sarcomas prior to any treatment. The spectra are characterized by the same peaks noted in murine tumors. The mean pH was 7.14 ± 0.08 and PCr/Pi was 1.18 ± 0.83. Comparison of pH and PCr/Pi, ratios in human and a murine tumor with a low hypoxic cell fraction revealed no significant differences. Six patients subsequently received chemotherapy and three responded to therapy (based on pathologic examination and/or tumor reduction greater than 50%). The three responding patients were noted to have significantly lower PDE/ PME in their pretreatment spectra than the three nonresponding patients. The three responding patients with sarcomas also showed a rise of > 100% in PDE/PME during the first cycle of therapy. Two of the responding patients had an increase of 0.37 pH units during this interval, which was not detected in the nonresponding patients. These data suggest that 31P NMR spectroscopy may be a useful prognostic indicator in conjunction with other clinical parameters. © 1990 Academic Press, Inc. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company |
Keywords: |
adult; clinical article; case report; cisplatin; doxorubicin; antineoplastic agents; comparative study; methodology; antineoplastic agent; animal cell; mouse; animal; mice; dacarbazine; phosphatase; etoposide; tumor markers, biological; cyclophosphamide; vincristine; tumor cells, cultured; tumor marker; ifosfamide; vinblastine; sarcoma; vincristine sulfate; chemistry; cell culture; limb; probability; remission; extremities; remission induction; magnetic resonance spectroscopy; nuclear magnetic resonance spectroscopy; phosphoric monoester hydrolases; nuclear magnetic resonance; soft tissue neoplasms; soft tissue tumor; nucleotide; phosphorus 31; phosphorus; computer analysis; middle age; nucleotides; creatine phosphate; sarcoma, experimental; phosphodiesterase; phosphocreatine; phosphoric diester hydrolases; human; male; female; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.
|